Pds Biotechnology Corp (PDSB)

$0.67 +0.01 (1.89%)
Market Cap 32.35M
Revenue (ttm) 0.00
Net Income (ttm) -37.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.26
Volume 199,700
Avg Vol 629,252
Day's Range N/A - N/A
Shares Out 48.98M
Stochastic %K 45%
Beta 1.20
Analysts Strong Sell
Price Target $7.50

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 208 3343
Address:
303A College Road East, Princeton, United States
Ontherag
Ontherag Mar. 7 at 1:15 AM
$PDSB Huge shout out to AF!
0 · Reply
dvice2
dvice2 Mar. 6 at 6:23 PM
$PDSB Year end cc should be next week if they even hold one..not that it means anything anymore
0 · Reply
Mr_Charlie
Mr_Charlie Mar. 6 at 1:51 PM
$PDSB pure shite of a stock.
0 · Reply
Eddie5150
Eddie5150 Mar. 6 at 1:03 PM
$PDSB
0 · Reply
Juliodough
Juliodough Mar. 4 at 5:14 PM
$PDSB good interview with Frank on TWST. worth seeking out.
4 · Reply
Test2025
Test2025 Mar. 4 at 4:31 PM
$PDSB
0 · Reply
Kosmokrat
Kosmokrat Mar. 4 at 2:14 PM
$PDSB I hope the support at 60 Cents keeps holding. But I don't see any major catalysts over the next few weeks to lift the price back up. Are there any good news to be expected any time soon?
2 · Reply
EddieH2020
EddieH2020 Mar. 4 at 1:27 PM
$PDSB I tried to help you all to SLS but you all didn’t listen. This is solely on you. ✌️
0 · Reply
Whyleb111
Whyleb111 Mar. 3 at 5:45 PM
$PDSB so are we going to ge delisted?!
3 · Reply
Ontherag
Ontherag Mar. 3 at 1:42 PM
$PDSB DesertDweller and AF are like best friends on X now 🤯
2 · Reply
Latest News on PDSB
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Feb 20, 2026, 8:30 AM EST - 14 days ago

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Jan 28, 2026, 8:45 AM EST - 5 weeks ago

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

Jan 22, 2026, 8:45 AM EST - 6 weeks ago

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Jan 9, 2026, 8:45 AM EST - 2 months ago

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 9, 2025, 8:00 AM EST - 3 months ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Dec 2, 2025, 8:30 AM EST - 3 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 10:11 AM EST - 4 months ago

PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 13, 2025, 7:30 AM EST - 4 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 11, 2025, 3:31 PM EST - 4 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 10, 2025, 8:30 AM EST - 4 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Nov 6, 2025, 8:00 AM EST - 4 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2025, 8:00 AM EDT - 4 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Oct 29, 2025, 8:37 AM EDT - 4 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 18, 2025, 8:45 AM EDT - 6 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 6 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 25, 2025, 8:30 AM EDT - 6 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 10:08 AM EDT - 7 months ago

PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 13, 2025, 7:00 AM EDT - 7 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Aug 6, 2025, 8:00 AM EDT - 7 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jul 10, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 9, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 2, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 10 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:57 PM EDT - 10 months ago

PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 14, 2025, 7:30 AM EDT - 10 months ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 4:05 PM EDT - 10 months ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 8, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

May 7, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:16 AM EDT - 11 months ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 8, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 10:35 AM EDT - 1 year ago

PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 27, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 25, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 18, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

PDS Biotech Leadership to Participate in March Conferences

Mar 11, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Participate in March Conferences

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Mar 7, 2025, 8:45 AM EST - 1 year ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 27, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 26, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 24, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Feb 20, 2025, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 11:18 AM EST - 1 year ago

PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

PDS Biotechnology: Continuing The Holding Pattern

Sep 23, 2024, 10:39 AM EDT - 1 year ago

PDS Biotechnology: Continuing The Holding Pattern

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Ontherag
Ontherag Mar. 7 at 1:15 AM
$PDSB Huge shout out to AF!
0 · Reply
dvice2
dvice2 Mar. 6 at 6:23 PM
$PDSB Year end cc should be next week if they even hold one..not that it means anything anymore
0 · Reply
Mr_Charlie
Mr_Charlie Mar. 6 at 1:51 PM
$PDSB pure shite of a stock.
0 · Reply
Eddie5150
Eddie5150 Mar. 6 at 1:03 PM
$PDSB
0 · Reply
Juliodough
Juliodough Mar. 4 at 5:14 PM
$PDSB good interview with Frank on TWST. worth seeking out.
4 · Reply
Test2025
Test2025 Mar. 4 at 4:31 PM
$PDSB
0 · Reply
Kosmokrat
Kosmokrat Mar. 4 at 2:14 PM
$PDSB I hope the support at 60 Cents keeps holding. But I don't see any major catalysts over the next few weeks to lift the price back up. Are there any good news to be expected any time soon?
2 · Reply
EddieH2020
EddieH2020 Mar. 4 at 1:27 PM
$PDSB I tried to help you all to SLS but you all didn’t listen. This is solely on you. ✌️
0 · Reply
Whyleb111
Whyleb111 Mar. 3 at 5:45 PM
$PDSB so are we going to ge delisted?!
3 · Reply
Ontherag
Ontherag Mar. 3 at 1:42 PM
$PDSB DesertDweller and AF are like best friends on X now 🤯
2 · Reply
Mr_Charlie
Mr_Charlie Mar. 3 at 10:45 AM
$PDSB dead cat walking
0 · Reply
EddieH2020
EddieH2020 Mar. 2 at 8:53 PM
$PDSB And again lol
0 · Reply
Marcino11
Marcino11 Mar. 2 at 8:40 AM
$PDSB According to the slide deck they are open for partners for PDS01ADC. It does not mention partners for PDS0101. Does someone know why? The potential in USD is higher for PDS01ADC. Does someone know more about the changes for this cure?
0 · Reply
Ontherag
Ontherag Feb. 28 at 1:39 AM
$PDSB
0 · Reply
KG1816
KG1816 Feb. 27 at 4:55 PM
$PDSB Sentiment desperately needs to shift
1 · Reply
Test2025
Test2025 Feb. 27 at 8:43 AM
$PDSB never been this dead with miniscule volume. "They" not bothered pretending it's alive?
0 · Reply
SteveJohnsonis
SteveJohnsonis Feb. 26 at 8:22 PM
$PDSB
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 26 at 8:19 PM
$PDSB Current Stock Price: $0.69 Contracts to trade: $2.5 PDSB Mar 20 2026 Call Entry: $0.04 Exit: $0.05 ROI: 28% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Bondra
Bondra Feb. 26 at 6:50 PM
$QURE DesertDweller 0/2 $PDSB
0 · Reply
KG1816
KG1816 Feb. 26 at 2:26 PM
$PDSB
0 · Reply
Mr_Charlie
Mr_Charlie Feb. 26 at 1:34 PM
$PDSB we might go 0.50's today. All way down until closing doors.
1 · Reply
Ontherag
Ontherag Feb. 26 at 12:39 AM
$PDSB Still in the zone
1 · Reply